🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 45 of 151

  1. Drug COVID19-0001-USR

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 2 small molecule active

    1 trial

  2. Drug GC4711

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  3. Drug Omega 3

    Matinas BioPharma Holdings

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  4. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. Drug-coated balloon angioplasty

    The First People's Hospital of Lianyungang

    Vertebral Artery Stenosis

    phase 2 other active

    1 trial

  6. Drug: B10 L-BPA Injection

    Heron Therapeutics

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  7. Drug: GC4419

    Galera Therapeutics

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  8. Drug: Pembrolizumab

    Hospital Authority, Hong Kong

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  9. Duobrii

    Bausch & Lomb Incorporated

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  10. Dupilumab

    Regeneron UK Limited

    Pruritis

    phase 2 small molecule active

    1 trial

  11. Dupilumab

    Regeneron UK Limited

    Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  12. Dupilumab

    Regeneron UK Limited

    Allergies Food Milk

    phase 2 small molecule terminated

    1 trial

  13. Dupilumab

    CATALYST PHARMACEUTICALS, INC.

    COVID-19

    phase 2 mab completed

    1 trial

  14. Dupilumab

    Hospital Authority, Hong Kong

    Nephrotic Syndrome in Children

    phase 2 mab active

    1 trial

  15. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  16. Dupilumab

    Coherus Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  17. Dupilumab

    Regeneron UK Limited

    Asthma, Allergic

    phase 2 small molecule active

    1 trial

  18. Dupilumab

    Regeneron UK Limited

    Eosinophilic Gastritis (EoG)

    phase 2 small molecule active

    1 trial

  19. Dupilumab

    Regeneron UK Limited

    Peanut Allergy

    phase 2 small molecule completed

    2 trials

  20. Dupilumab

    Regeneron UK Limited

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  21. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  22. Dupilumab

    Regeneron UK Limited

    Atopic Keratoconjunctivitis

    phase 2 small molecule active

    1 trial

  23. Dupilumab (blinded)

    Regeneron UK Limited

    Eosinophilic Gastritis

    phase 2 small molecule completed

    1 trial

  24. Dupilumab 300Mg Solution for Injection

    Regeneron UK Limited

    Pruritus

    phase 2 small molecule completed

    1 trial

  25. Dupixent®

    Regeneron UK Limited

    Allergic Rhinoconjunctivitis

    phase 2 mab completed

    1 trial

  26. Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  27. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  28. Durvalumab

    United Therapeutics Europe Ltd

    Stage IB Hepatocellular Carcinoma AJCC v8

    phase 2 mab active

    1 trial

  29. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  30. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  31. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  32. E. coli ETVAX

    United Therapeutics Europe Ltd

    Diarrhea

    phase 2 mab completed

    1 trial

  33. E004 (epinephrine inhalation aerosol), 90 mcg/actuation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  34. E6005

    Organon Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  35. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  36. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  37. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  38. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  39. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  40. EB01 Cream Placebo

    Edesa Biotech

    Allergic Contact Dermatitis

    phase 2 small molecule completed

    1 trial

  41. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  42. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  43. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  44. EDG-5506, EDG-5506

    Edgewise Therapeutics

    Becker Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  45. EDG-7500

    Edgewise Therapeutics

    Hypertrophic Cardiomyopathy

    phase 2 small molecule active

    1 trial

  46. EDIT-101

    Editas Medicine

    Leber Congenital Amaurosis 10

    phase 2 small molecule active

    1 trial

  47. EDIT-301

    Editas Medicine

    Sickle Cell Disease

    phase 2 gene therapy active

    1 trial

  48. EDIT-301

    Editas Medicine

    Transfusion Dependent Beta Thalassemia

    phase 2 gene therapy active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.